Q-omics provides the consensus-scored SYNRG profile across patient tissues and cancer cell-line models. SYNRG expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SYNRG is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, SYNRG RNA expression shows 21,244 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where SYNRG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYNRG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYNRG survival associations across molecular data types. SYNRG RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYNRG RNA expression–survival associations across cancer types. High SYNRG expression shows favorable associations in KIRC, HNSC, ESCA, BRCA, UCS and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SYNRG RNA expression.
This table summarizes SYNRG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SYNRG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYNRG shows lower tumor expression in COAD, KICH and THCA and higher tumor expression in CHOL, LIHC and STAD. The COAD box plot shows higher SYNRG RNA expression in normal versus tumor tissue (log2 FC = −0.647, t-test p < 0.001).
This table shows molecular features associated with SYNRG in patient tissues and cancer cell lines. In patient samples, SYNRG shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SYNRG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
